DK1076657T3 - Hidtil ukendte hydroxyindoler, deres anvendelse som inhibitorer for phosphodiesterase 4 og fremgangsmåde til deres fremstilling - Google Patents

Hidtil ukendte hydroxyindoler, deres anvendelse som inhibitorer for phosphodiesterase 4 og fremgangsmåde til deres fremstilling

Info

Publication number: DK1076657T3
Authority: DK; Denmark
Prior art keywords: phosphodiesterase; inhibitors; preparation; new hydroxy; hydroxy indoles
Prior art date: 1998-04-28

Application number

DK99920779T

Other languages

English (en)

Inventor

Hildegard Poppe

Thomas Kronbach

Norbert Hoefgen

Ute Egerland

Degenhard Marx

Stefan Szelenyi

Emmanuel Polymeropoulos

Sabine Heer

Original Assignee

Elbion Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-04-28

Filing date

1999-04-24

Publication date

2004-11-08

1998-04-28 Priority claimed from DE19818964A external-priority patent/DE19818964A1/de

1999-04-17 Priority claimed from DE1999117504 external-priority patent/DE19917504A1/de

1999-04-24 Application filed by Elbion Ag filed Critical Elbion Ag

2004-11-08 Application granted granted Critical

2004-11-08 Publication of DK1076657T3 publication Critical patent/DK1076657T3/da

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D209/22—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an aralkyl radical attached to the ring nitrogen atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/04—Drugs for disorders of the urinary system for urolithiasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D209/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an alkyl or cycloalkyl radical attached to the ring nitrogen atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Bioinformatics & Cheminformatics (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Immunology (AREA)
Physical Education & Sports Medicine (AREA)
Urology & Nephrology (AREA)
Pulmonology (AREA)
Diabetes (AREA)
Dermatology (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Psychiatry (AREA)
Tropical Medicine & Parasitology (AREA)
Oncology (AREA)
Addiction (AREA)
Hematology (AREA)
Communicable Diseases (AREA)
Pain & Pain Management (AREA)
Virology (AREA)
Psychology (AREA)
Vascular Medicine (AREA)
Molecular Biology (AREA)
Ophthalmology & Optometry (AREA)

DK99920779T 1998-04-28 1999-04-24 Hidtil ukendte hydroxyindoler, deres anvendelse som inhibitorer for phosphodiesterase 4 og fremgangsmåde til deres fremstilling DK1076657T3 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
DE19818964A DE19818964A1 (de)	1998-04-28	1998-04-28	Neue Hydroxyindole, deren Verwendung als Inhibitoren der Phospodiesterase 4 und Verfahren zu deren Herstellung
DE1999117504 DE19917504A1 (de)	1999-04-17	1999-04-17	Verwendung von Hydroxyindolen, die Inhibitoren der Phosphodiesterase 4 sind, zur Therapie chronisch obstruktiver Lungenerkrankungen
EP99920779A EP1076657B1 (de)	1998-04-28	1999-04-24	Neue hydroxyindole, deren verwendung als inhibitoren der phosphodiesterase 4 und verfahren zu deren herstellung

Publications (1)

Publication Number	Publication Date
DK1076657T3 true DK1076657T3 (da)	2004-11-08

Family

ID=26045814

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK99920779T DK1076657T3 (da)	1998-04-28	1999-04-24	Hidtil ukendte hydroxyindoler, deres anvendelse som inhibitorer for phosphodiesterase 4 og fremgangsmåde til deres fremstilling
DK04018391T DK1475377T3 (da)	1998-04-28	1999-04-24	Indol-derivater og deres anvendelse som inhibitorer for phosphodiesterase 4

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
DK04018391T DK1475377T3 (da)	1998-04-28	1999-04-24	Indol-derivater og deres anvendelse som inhibitorer for phosphodiesterase 4

Country Status (27)

Country	Link
US (8)	US6251923B1 (da)
EP (2)	EP1076657B1 (da)
JP (2)	JP3842043B2 (da)
KR (1)	KR100448748B1 (da)
CN (1)	CN1234705C (da)
AR (1)	AR016236A1 (da)
AT (2)	ATE330955T1 (da)
AU (1)	AU748403B2 (da)
BG (1)	BG65023B1 (da)
BR (1)	BR9910029A (da)
CY (1)	CY1105075T1 (da)
CZ (1)	CZ20003985A3 (da)
DE (2)	DE59913617D1 (da)
DK (2)	DK1076657T3 (da)
ES (2)	ES2222706T3 (da)
HU (1)	HUP0101625A3 (da)
IL (2)	IL138847A0 (da)
NO (1)	NO321867B1 (da)
NZ (1)	NZ507406A (da)
PL (1)	PL198983B1 (da)
PT (2)	PT1475377E (da)
SI (2)	SI1076657T1 (da)
SK (1)	SK286192B6 (da)
TR (1)	TR200003130T2 (da)
TW (1)	TW530048B (da)
UA (1)	UA59443C2 (da)
WO (1)	WO1999055696A1 (da)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE19946301A1 (de)	1998-04-02	2001-04-19	Asta Medica Ag	Indolyl-3-glyoxylsäure-Derivate mit therapeutisch wertvollen Eigenschaften
DE19814838C2 (de) *	1998-04-02	2001-01-18	Asta Medica Ag	Indolyl-3-glyoxylsäure-Derivate mit Antitumorwirkung
TR200003130T2 (tr) *	1998-04-28	2001-01-22	Arzneimittelwerk Dresden Gmbh	Yeni hidroksiindoller, bunların fosfodiesteraz 4 inhibitörleri olarak kullanımları ve hazırlanmaları için işlemler
AU4834200A (en) *	1999-05-10	2000-11-21	Protarga, Inc.	Fatty acid-n-substituted indol-3-glyoxyl-amide compositions and uses thereof
DE19924138A1 (de)	1999-05-26	2000-11-30	Henkel Kgaa	Lösbare Klebeverbindungen
US6469006B1 (en) *	1999-06-15	2002-10-22	Bristol-Myers Squibb Company	Antiviral indoleoxoacetyl piperazine derivatives
TWI269654B (en) *	1999-09-28	2007-01-01	Baxter Healthcare Sa	N-substituted indole-3-glyoxylamide compounds having anti-tumor action
DE19951599A1 (de) *	1999-10-27	2001-05-23	Henkel Kgaa	Verfahren zur adhesiven Trennung von Klebeverbunden
IT1315267B1 (it) *	1999-12-23	2003-02-03	Novuspharma Spa	Derivati di 2-(1h-indol-3-il)-2-oxo-acetammidi ad attivita'antitumorale
DE19962300A1 (de) *	1999-12-23	2001-06-28	Asta Medica Ag	Substituierte N-Benzyl-Indol-3-yl-glyoxylsäure-Derivate mit Antitumorwirkung
US6436965B1 (en)	2000-03-02	2002-08-20	Merck Frosst Canada & Co.	PDE IV inhibiting amides, compositions and methods of treatment
US6573262B2 (en)	2000-07-10	2003-06-03	Bristol-Myers Sqibb Company	Composition and antiviral activity of substituted indoleoxoacetic piperazine derivatives
IT1318641B1 (it) *	2000-07-25	2003-08-27	Novuspharma Spa	Ammidi di acidi 2-(1h-indol-3-il)-2-oxo-acetici ad attivita'antitumorale.
DE10037310A1 (de)	2000-07-28	2002-02-07	Asta Medica Ag	Neue Indolderivate und deren Verwendung als Arzneimittel
DE10037884A1 (de) *	2000-08-03	2002-02-21	Henkel Kgaa	Verfahren zur beschleunigten Klebstoffaushärtung
US6903104B2 (en) *	2001-12-06	2005-06-07	National Health Research Institutes	Indol-3-YL-2-oxoacetamide compounds and methods of use thereof
US7752681B2 (en)	2002-05-24	2010-07-13	Michel Licensing, Inc.	Article of clothing with wicking portion
TW200400177A (en)	2002-06-04	2004-01-01	Wyeth Corp	1-(Aminoalkyl)-3-sulfonylindole and-indazole derivatives as 5-hydroxytryptamine-6 ligands
UA78999C2 (en) *	2002-06-04	2007-05-10	Wyeth Corp	1-(aminoalkyl)-3-sulfonylazaindoles as ligands of 5-hydroxytryptamine-6
US20040038958A1 (en) *	2002-07-11	2004-02-26	Chris Rundfeldt	Topical treatment of skin diseases
HRP20050201A2 (en)	2002-08-01	2005-04-30	Elbion Ag	Method for producing highly pure hydroxy indolyl glyoxylic acid amideslyoxylic acid amides
UA82323C2 (uk) *	2002-08-09	2008-04-10	Меда Фарма Гмбх & Ко. Кг	Нова комбінація глюкокортикоїду та pde-інгібітору для лікування респіраторних захворювань, алергічних захворювань, астми та хронічних обструктивних легеневих захворювань
DE10253426B4 (de) *	2002-11-15	2005-09-22	Elbion Ag	Neue Hydroxyindole, deren Verwendung als Inhibitoren der Phosphodiesterase 4 und Verfahren zu deren Herstellung
DE10318611A1 (de)	2003-04-24	2004-11-11	Elbion Ag	4-, 6- oder 7-Hydroxyindole mit N-Oxidgruppen und deren Verwendung als Therapeutika
DE10318609A1 (de) *	2003-04-24	2004-11-11	Elbion Ag	5-Hydroxyindole mit N-Oxidgruppen und deren Verwendung als Therapeutika
DE10318610A1 (de)	2003-04-24	2004-11-11	Elbion Ag	7-Azaindole und deren Verwendung als Therapeutika
WO2004098606A1 (en) *	2003-05-12	2004-11-18	Altana Pharma Ag	Composition comprising a pde4 inhibitor and shuil-1r ii
WO2004098578A2 (en) *	2003-05-12	2004-11-18	Altana Pharma Ag	Composition comprising a pde4 inhibitor and a tnf-alfa antagonist selected from infliximab, adalimumab, cdp870 and cdp517
US7205299B2 (en) *	2003-06-05	2007-04-17	Zentaris Gmbh	Indole derivatives having an apoptosis-inducing effect
US7211588B2 (en) *	2003-07-25	2007-05-01	Zentaris Gmbh	N-substituted indolyl-3-glyoxylamides, their use as medicaments and process for their preparation
US20050187278A1 (en) *	2003-08-28	2005-08-25	Pharmacia Corporation	Treatment or prevention of vascular disorders with Cox-2 inhibitors in combination with cyclic AMP-specific phosphodiesterase inhibitors
WO2005023761A2 (en) *	2003-09-11	2005-03-17	Kemia, Inc.	Cytokine inhibitors
US20070105937A1 (en) *	2003-12-22	2007-05-10	Miguel Pappolla	Indole-3-propionamide and derivatives thereof
DE102004031538A1 (de) *	2004-06-29	2006-02-09	Baxter International Inc., Deerfield	Pharmazeutische Darreichungsform zur oralen Verabreichung eines schwerlöslichen Wirkstoffs, Verfahren zu deren Herstellung und Kit
EP1813284A1 (en) *	2004-10-13	2007-08-01	Kyowa Hakko Kogyo Co., Ltd.	Pharmaceutical composition
US20070287689A1 (en) *	2004-10-13	2007-12-13	Kyowa Hakko Kogyo Co., Ltd.	Therapeutic And/Or Preventive Agents For Chronic Skin Diseases
WO2006052712A1 (en) *	2004-11-08	2006-05-18	Baxter International Inc.	Nanoparticulate compositions of tubulin inhibitor
TW200738677A (en) *	2005-06-27	2007-10-16	Elbion Ag	Nitro-substituted hydroxyindoles, their use as inhibitors of phosphodiesterase 4, and processes for preparing them
EP2258357A3 (en)	2005-08-26	2011-04-06	Braincells, Inc.	Neurogenesis with acetylcholinesterase inhibitor
CA2620333A1 (en)	2005-08-26	2007-03-01	Braincells, Inc.	Neurogenesis by muscarinic receptor modulation
WO2007045979A1 (en)	2005-10-19	2007-04-26	Ranbaxy Laboratories Limited	Pharmaceutical compositions of muscarinic receptor antagonists
JP2009512711A (ja)	2005-10-21	2009-03-26	ブレインセルス，インコーポレイティド	Ｐｄｅ阻害による神経新生の調節
US20070112017A1 (en)	2005-10-31	2007-05-17	Braincells, Inc.	Gaba receptor mediated modulation of neurogenesis
TWI435729B (zh)	2005-11-09	2014-05-01	Combinatorx Inc	治療病症之方法，組合物及套組
BRPI0706523A2 (pt)	2006-01-13	2011-01-04	Wyeth Corp	composto de fórmula i; composição farmacêutica; método de tratamento de distúrbios que estão relacionados com ou são afetados pela inibição da recaptação de norepinefrina, o receptor de 5-ht6 ou o receptor de 5-ht2a; método de tratamento de um distúrbio de aprendizado, de um distúrbio cognitivo, de um distúrbio de memória, de um distúrbio de personalidade, de um distúrbio comportamental, de um distúrbio de movimento, de um distúrbio neurodegenerativo, de abstinência de droga, de distúrbio de sono, de um distúrbio alimentar, de uma toxicidade de droga aguda, de um distúrbio cardiovascular, de uma disfunção sexual, de um distúrbio gastrintestinal, de um distúrbio genitourinário, de um distúrbio de dor, de um distúrbio nervoso ou de um distúrbio de sintoma vasomotor; método de tratamento de doença de alzheimer, de um distúrbio de deficiência da atenção, de esquizofrenia, de doença de parkinson, de discinésia tardia, de ataxia, de bradicinésia, de discinésias paroxìsmicas, de sìndrome da perna irrequieta, de tremor, de tremor essencial, de epilepsia, de apoplexia ou de trauma na cabeça; método de tratamento de doença arterial coronariana, de enfarte do miocárdio, de ataque isquêmico transitório, de angina, de fibrilação atrial, de agregação plaquetária, de risco de formação de coágulo sanguìneo, de sìndrome do intestino irritável, de constipação crÈnica, de doença do refluxo gastrintestinal, de dispepsia, de incontinência urinária por estresse ou de incontinência urinária de urgência; método de tratamento de depressão, de distúrbio compulsivo obsessivo, de tendência ao suicìdio, de distúrbio de ansiedade, de distúrbio bipolar, de distúrbio de pánico, de abstinência de nicotina, de abstinência de álcool, de abstinência de cocaìna, de abstinência de heroìna, de abstinência de anfetamina, de abstinência de drogas narcóticas, de insÈnia, de apnéia do sono, de narcolepsia, de distúrbio afetivo sanzonal, de sìndrome da perna irrequieta, de distúrbio de sono de turno de trabalho, de sìndrome da fase do sono retardada, de anorexia nervosa, de bulimia nervosa, de sìndrome do comer noturno, de superalimentação compulsiva, de sìndrome da fadiga crÈnica, de fibromialgia, de neuropatia de dor, de dor antinociceptiva, de sìndrome da dor crÈnica, de neuropatia diabética, de fogacho ou de suor noturno; e uso de um composto
US20100216734A1 (en)	2006-03-08	2010-08-26	Braincells, Inc.	Modulation of neurogenesis by nootropic agents
EP2382975A3 (en)	2006-05-09	2012-02-29	Braincells, Inc.	Neurogenesis by modulating angiotensin
CA2651862A1 (en)	2006-05-09	2007-11-22	Braincells, Inc.	5 ht receptor mediated neurogenesis
RS53084B (sr)	2006-07-05	2014-06-30	Takeda Gmbh	Kombinacija inhibitora hmg-coa reduktaze rosuvastatina sa inhibitorom fosfodiesteraze 4, kao što je roflumilast, roflumilast-n-oksid za lečenje inflamatornih plućnih obolenja
WO2008019357A2 (en) *	2006-08-07	2008-02-14	Ironwood Pharmaceuticals, Inc.	Indole compounds
JP2010502722A (ja)	2006-09-08	2010-01-28	ブレインセルス，インコーポレイティド	４−アシルアミノピリジン誘導体を含む組み合わせ
US20100184806A1 (en)	2006-09-19	2010-07-22	Braincells, Inc.	Modulation of neurogenesis by ppar agents
CA2670778A1 (en) *	2006-11-28	2008-06-05	Ziopharm Oncology, Inc.	Use of indolyl-3-glyoxylic acid derivatives including indibulin, alone or in combination with further agents for treating cancer
CN101657460A (zh) *	2006-12-13	2010-02-24	基利得科学公司	用于治疗肺炎症和支气管收缩的作为抗炎性信号转导调节剂(AISTM’S)和β-激动剂的相互前药的单磷酸酯
US20090182035A1 (en) *	2007-04-11	2009-07-16	Alcon Research, Ltd.	Use of a combination of olopatadine and cilomilast to treat non-infectious rhinitis and allergic conjunctivitis
US20080254029A1 (en) *	2007-04-11	2008-10-16	Alcon Research, Ltd.	Use of an Inhibitor of TNFa Plus an Antihistamine to Treat Allergic Rhinitis and Allergic Conjunctivitis
US7750027B2 (en) *	2008-01-18	2010-07-06	Oxagen Limited	Compounds having CRTH2 antagonist activity
WO2010099217A1 (en)	2009-02-25	2010-09-02	Braincells, Inc.	Modulation of neurogenesis using d-cycloserine combinations
CN102548536A (zh) *	2009-10-01	2012-07-04	爱尔康研究有限公司	奥洛他定组合物及其用途
AR084433A1 (es)	2010-12-22	2013-05-15	Ironwood Pharmaceuticals Inc	Inhibidores de la faah y composiciones farmaceuticas que los contienen
EP2804603A1 (en)	2012-01-10	2014-11-26	President and Fellows of Harvard College	Beta-cell replication promoting compounds and methods of their use
GB201407820D0 (en)	2014-05-02	2014-06-18	Atopix Therapeutics Ltd	Polymorphic form
GB201407807D0 (en)	2014-05-02	2014-06-18	Atopix Therapeutics Ltd	Polymorphic form
US20190016680A1 (en)	2016-01-14	2019-01-17	Beth Israel Deaconess Medical Center, Inc.	Mast-cell modulators and uses thereof
AU2019417718A1 (en)	2018-12-28	2021-07-08	Regeneron Pharmaceuticals, Inc.	Treatment of respiratory disorders with Arachidonate 15-Lipoxygenase (ALOX15) inhibitors
US11674450B1 (en)	2021-12-13	2023-06-13	Pratt & Whitney Canada Corp.	System and method for synthesizing engine thrust

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NL100127C (da)	1954-04-28
US2870162A (en)	1954-04-28	1959-01-20	Upjohn Co	Production of certain tryptamines and compounds produced in the process
US2825734A (en)	1955-04-11	1958-03-04	Upjohn Co	Reduction of carbonylic radicals in indolyl-3 compounds
US2930797A (en)	1957-11-22	1960-03-29	Upjohn Co	2-alkyl-3-indoleglyoxylamides
GB944443A (da)	1959-09-25	1900-01-01
US3028393A (en)	1960-05-11	1962-04-03	Upjohn Co	Novel 1-(3-indoyl)-1, 2-alkanediols and substituted hydroxymethyl 3-in-dolyl ketones
US3196162A (en)	1961-03-13	1965-07-20	Merck & Co Inc	Indolyl aliphatic acids
US3271416A (en)	1961-10-24	1966-09-06	Merck & Co Inc	Indolyl aliphatic acids
US3259622A (en)	1962-09-07	1966-07-05	Merck & Co Inc	1-benzyl-3-indolyl-alpha-haloalkyl and alkylidenyl acetic acids
US3238215A (en)	1963-10-17	1966-03-01	Sterling Drug Inc	1-[(3-, 2-, and 1-indolyl)-lower-alkyl-, lower-alkenyl-, and lower-alkynyl]piperidines
US3342834A (en)	1964-03-02	1967-09-19	Merck & Co Inc	Indolyl alkenoic acids
US3821387A (en)	1965-10-23	1974-06-28	Robins Co Inc A H	The treatment of parkinsonism with 3-(omega-substituted alkyl)-indoles
US3459770A (en)	1966-12-07	1969-08-05	American Home Prod	Indoleglyoxyloylpyrroles
US3527261A (en)	1968-11-12	1970-09-08	Babcock & Wilcox Co	Tube guide apparatus
US3578669A (en)	1969-09-16	1971-05-11	Sterling Drug Inc	1-((2 - substituted - 3 - indolyl) - lower-alkanoyl) - cycloalkyl - lower-alkylpiperidines and 1 - ((2 - hydroxymethyl-3 - indolyl)-lower-alkayl)-cycloalkyl-lower-alkylpiperidines
US5192770A (en)	1990-12-07	1993-03-09	Syntex (U.S.A.) Inc.	Serotonergic alpha-oxoacetamides
EP0654024A1 (en) *	1992-08-06	1995-05-24	Warner-Lambert Company	2-thioindoles (selenoindoles) and related disulfides (selenides) which inhibit protein tyrosine kinases and which have antitumor properties
EP0672031B1 (en)	1992-12-02	2003-03-12	Pfizer Inc.	Catechol diethers as selective pde iv inhibitors
ES2156120T3 (es) *	1992-12-08	2001-06-16	Ss Pharmaceutical Co	Derivados arilamidicos.
US5424329A (en)	1993-08-18	1995-06-13	Warner-Lambert Company	Indole-2-carboxamides as inhibitors of cell adhesion
US5502072A (en)	1993-11-26	1996-03-26	Pfizer Inc.	Substituted oxindoles
US5489586A (en)	1994-03-07	1996-02-06	Warner-Lambert Company	Method for treating inflammatory disease in humans
FI971334L (fi)	1994-08-03	1997-04-01	Asta Medica Ag	Indoli-, indatsoli-, pyridopyrroli- ja pyridopyratsolijohdannaiset, joilla on antiastmaattinen, antiallerginen, anti-inflammatorinen ja immunomoduloiva vaikutus
DE19511916A1 (de)	1994-08-03	1996-02-08	Asta Medica Ag	Neue N-Benzylindol- und Benzopyrazol-Derivate mit antiasthmatischer, antiallergischer, entzündungshemmender und immunmodulierender Wirkung
US5728844A (en) *	1995-08-29	1998-03-17	Celgene Corporation	Immunotherapeutic agents
TW429148B (en)	1995-10-27	2001-04-11	Pfizer	Pharmaceutical agents for the treatment of acute and chronic inflammatory diseases
WO1997048697A1 (en)	1996-06-19	1997-12-24	Rhone-Poulenc Rorer Limited	Substituted azabicylic compounds and their use as inhibitors of the production of tnf and cyclic amp phosphodiesterase
EP0920306A2 (en)	1996-07-12	1999-06-09	Leukosite, Inc.	Chemokine receptor antagonists and methods of use therefor
WO1998008818A1 (en)	1996-08-26	1998-03-05	Genetics Institute, Inc.	Inhibitors of phospholipase enzymes
DE19636150A1 (de) *	1996-09-06	1998-03-12	Asta Medica Ag	N-substituierte Indol-3-glyoxylamide mit antiasthmatischer, antiallergischer und immunsuppressiver/immunmodulierender Wirkung
TR200003130T2 (tr) *	1998-04-28	2001-01-22	Arzneimittelwerk Dresden Gmbh	Yeni hidroksiindoller, bunların fosfodiesteraz 4 inhibitörleri olarak kullanımları ve hazırlanmaları için işlemler
IT1315267B1 (it)	1999-12-23	2003-02-03	Novuspharma Spa	Derivati di 2-(1h-indol-3-il)-2-oxo-acetammidi ad attivita'antitumorale

1999
- 1999-04-24 TR TR2000/03130T patent/TR200003130T2/xx unknown
- 1999-04-24 BR BR9910029-0A patent/BR9910029A/pt not_active Application Discontinuation
- 1999-04-24 JP JP2000545856A patent/JP3842043B2/ja not_active Expired - Fee Related
- 1999-04-24 AT AT04018391T patent/ATE330955T1/de not_active IP Right Cessation
- 1999-04-24 WO PCT/EP1999/002792 patent/WO1999055696A1/de not_active Ceased
- 1999-04-24 CZ CZ20003985A patent/CZ20003985A3/cs unknown
- 1999-04-24 SI SI9930670T patent/SI1076657T1/xx unknown
- 1999-04-24 UA UA2000116726A patent/UA59443C2/uk unknown
- 1999-04-24 PL PL343569A patent/PL198983B1/pl unknown
- 1999-04-24 ES ES99920779T patent/ES2222706T3/es not_active Expired - Lifetime
- 1999-04-24 SK SK1575-2000A patent/SK286192B6/sk not_active IP Right Cessation
- 1999-04-24 EP EP99920779A patent/EP1076657B1/de not_active Expired - Lifetime
- 1999-04-24 EP EP04018391A patent/EP1475377B1/de not_active Expired - Lifetime
- 1999-04-24 KR KR10-2000-7011992A patent/KR100448748B1/ko not_active Expired - Fee Related
- 1999-04-24 PT PT04018391T patent/PT1475377E/pt unknown
- 1999-04-24 PT PT99920779T patent/PT1076657E/pt unknown
- 1999-04-24 ES ES04018391T patent/ES2262072T3/es not_active Expired - Lifetime
- 1999-04-24 IL IL13884799A patent/IL138847A0/xx active IP Right Grant
- 1999-04-24 NZ NZ507406A patent/NZ507406A/xx unknown
- 1999-04-24 DE DE59913617T patent/DE59913617D1/de not_active Expired - Fee Related
- 1999-04-24 DE DE59910142T patent/DE59910142D1/de not_active Expired - Fee Related
- 1999-04-24 SI SI9930922T patent/SI1475377T1/sl unknown
- 1999-04-24 AU AU38229/99A patent/AU748403B2/en not_active Ceased
- 1999-04-24 DK DK99920779T patent/DK1076657T3/da active
- 1999-04-24 AT AT99920779T patent/ATE272631T1/de not_active IP Right Cessation
- 1999-04-24 HU HU0101625A patent/HUP0101625A3/hu unknown
- 1999-04-24 DK DK04018391T patent/DK1475377T3/da active
- 1999-04-24 CN CNB998079766A patent/CN1234705C/zh not_active Expired - Fee Related
- 1999-04-28 AR ARP990101965A patent/AR016236A1/es active IP Right Grant
- 1999-04-28 TW TW088106886A patent/TW530048B/zh not_active IP Right Cessation
- 1999-04-28 US US09/300,973 patent/US6251923B1/en not_active Ceased
2000
- 2000-10-04 IL IL138847A patent/IL138847A/en not_active IP Right Cessation
- 2000-10-11 BG BG104842A patent/BG65023B1/bg unknown
- 2000-10-27 NO NO20005454A patent/NO321867B1/no unknown
2002
- 2002-02-21 US US10/081,642 patent/US7161009B2/en not_active Expired - Fee Related
- 2002-02-21 US US10/081,807 patent/US6602890B2/en not_active Expired - Fee Related
- 2002-02-21 US US10/080,821 patent/US6545025B2/en not_active Expired - Fee Related
- 2002-02-21 US US10/081,395 patent/US6545158B2/en not_active Expired - Fee Related
- 2002-09-19 US US10/176,435 patent/USRE38624E1/en not_active Expired - Fee Related
2003
- 2003-01-20 US US10/347,659 patent/US6613794B2/en not_active Expired - Fee Related
2004
- 2004-05-27 US US10/856,034 patent/US20040220183A1/en not_active Abandoned
2006
- 2006-03-27 JP JP2006086619A patent/JP2006249091A/ja not_active Withdrawn
- 2006-07-07 CY CY20061100948T patent/CY1105075T1/el unknown

Also Published As

Publication number	Publication date
TW530048B (en)	2003-05-01
EP1475377A8 (de)	2005-01-19
US20020111351A1 (en)	2002-08-15
DE59910142D1 (de)	2004-09-09
EP1475377A1 (de)	2004-11-10
JP2006249091A (ja)	2006-09-21
US7161009B2 (en)	2007-01-09
KR20010043106A (ko)	2001-05-25
ATE330955T1 (de)	2006-07-15
JP2002513017A (ja)	2002-05-08
DE59913617D1 (de)	2006-08-03
SI1475377T1 (sl)	2006-12-31
US20020115651A1 (en)	2002-08-22
NO321867B1 (no)	2006-07-17
BG65023B1 (bg)	2006-12-29
BG104842A (en)	2001-10-31
CN1234705C (zh)	2006-01-04
US6613794B2 (en)	2003-09-02
HUP0101625A3 (en)	2002-12-28
KR100448748B1 (ko)	2004-09-18
EP1076657B1 (de)	2004-08-04
ES2222706T3 (es)	2005-02-01
EP1076657A1 (de)	2001-02-21
HUP0101625A2 (hu)	2001-11-28
CN1307575A (zh)	2001-08-08
NO20005454L (no)	2000-12-07
IL138847A0 (en)	2001-10-31
AR016236A1 (es)	2001-06-20
US6251923B1 (en)	2001-06-26
PT1475377E (pt)	2006-11-30
CZ20003985A3 (cs)	2001-09-12
TR200003130T2 (tr)	2001-01-22
EP1475377B1 (de)	2006-06-21
WO1999055696A1 (de)	1999-11-04
CY1105075T1 (el)	2010-03-03
ATE272631T1 (de)	2004-08-15
NO20005454D0 (no)	2000-10-27
US20020137745A1 (en)	2002-09-26
US20040220183A1 (en)	2004-11-04
US6545025B2 (en)	2003-04-08
HK1035183A1 (en)	2001-11-16
PT1076657E (pt)	2004-11-30
US20030134876A1 (en)	2003-07-17
SK286192B6 (sk)	2008-05-06
PL198983B1 (pl)	2008-08-29
SK15752000A3 (sk)	2001-08-06
JP3842043B2 (ja)	2006-11-08
US6602890B2 (en)	2003-08-05
DK1475377T3 (da)	2006-10-23
BR9910029A (pt)	2000-12-26
AU3822999A (en)	1999-11-16
SI1076657T1 (en)	2004-12-31
ES2262072T3 (es)	2006-11-16
NZ507406A (en)	2002-11-26
USRE38624E1 (en)	2004-10-12
UA59443C2 (uk)	2003-09-15
AU748403B2 (en)	2002-06-06
IL138847A (en)	2006-08-20
US6545158B2 (en)	2003-04-08
PL343569A1 (en)	2001-08-27
US20020119971A1 (en)	2002-08-29

Publication	Publication Date	Title
DK1076657T3 (da)	2004-11-08	Hidtil ukendte hydroxyindoler, deres anvendelse som inhibitorer for phosphodiesterase 4 og fremgangsmåde til deres fremstilling
DK0950657T3 (da)	2004-11-22	Substituerede carbazoler, fremgangsmåde til deres fremstilling og deres anvendelse som sPLA2-inhibitorer
DK1202733T3 (da)	2005-10-31	3(5)-amino-pyrazolderivater, fremgangsmåde til deres fremstilling og deres anvendelse som antitumormidler
NO20012058L (no)	2001-06-28	2-ureido-tiazolderivater, fremgangsmåte for deres fremstilling og anvendelse som antitumormidler
NO986103D0 (no)	1998-12-23	Substituerte indazol-derivater og deres anvendelse som fosfodiesterase (PDE
NO20020687D0 (no)	2002-02-11	3(5)-ureidopyrazolderivater, fremgangsmåte for fremstilling av disse og deres anvendelse som antitumormidler
NO20012057L (no)	2001-06-28	2-amino-tiazolderivater, fremgangsmåte for deres fremstilling og anvendelse som antitumormidler
DK1330455T3 (da)	2005-12-05	Hidtil ukendte 7-azaindoler, deres anvendelse som inhibitorer for phosphodiesterase 4 og fremgangsmåde til deres fremstilling
NO20003972L (no)	2001-02-06	Borefluid og vedlikeholdsfluid, fremgangsmåte for deres fremstilling samt anvendelse derav
NO20032229D0 (no)	2003-05-16	Fremgangsmåter for behandling av p38kinase-assosierte tilstander og pyrrolotriazin forbindelser nyttige som kinase inhibitorer
AU2002212226A1 (en)	2002-03-22	Use of indole derivatives for treating illnesses of the central nervous system
DK1244647T3 (da)	2006-09-25	Quinzolinderivater som VIGF-inhibitorer
NO20010309L (no)	2001-04-11	Ikke-peptidiske midler for inhibering av gonatropinfrigjörende hormoner, samt fremgangsmåter og mellomprodukter til fremstilling derav
IS6531A (is)	2002-08-28	Aðferðir til að búa til klaríþrómýsín og klaríþrómýsínmilliefni, í megindráttum oxímlaust klaríþrómýsín og lyfjablanda sem inniheldur það
NO20010331L (no)	2001-03-20	Ftalazinderivater som fosfodiesterase 4-inhibitorer
NO20003070L (no)	2000-06-15	Substituert tiazolidinderivat, fremgangsmÕte for fremstilling og anvendelse derav
NO20015062D0 (no)	2001-10-18	Substituerte 3-cyano-[1.7],[1.5]og[1.8]-naftyridin- inhibitorer for tyrosin-kinaser
DK0795547T3 (da)	2000-09-18	(Aminoalkyl- og acylaminoalkyl-oxy)benzyloxyquinoliner, fremgangsmåde til deres fremstilling og deres anvendelse som bradyk
DK0782575T3 (da)	2003-05-12	Substituerede pyrazol-pyrazol-derivater, fremgangsmåde til deres fremsstilling samt deres anvendelse som midler med herbicid virkning
DK1214302T3 (da)	2004-02-16	Substituerede 3-phenyl-5-alkoxy-1,3,4-oxadiazol-2-oner og deres anvendelse som lipasehæmmere
NO990913D0 (no)	1999-02-25	Naftylforbindelser, intermediater, sammensetninger og metoder for anvendelse
DK1341758T3 (da)	2006-10-30	Coniosetin og derivater af denne, fremgangsmåde til fremstilling og anvendelse af samme
NO20020308D0 (no)	2002-01-21	Fremgangsmåte for fremstilling av epothiolon B og derivater, såvel som mellomprodukter for fremgangsmåten
NO20035642L (no)	2004-02-12	Fremgangsmate for fremstilling av derivater av 1,5-diaryl-3-trifluormetyl-delta2-pyrazoliner som er racemisk og enantiomerisk rene
NO20025885L (no)	2003-01-29	Derivater av 4,5-dihydro-tiazo-2-ylamin og deres anvendelse som NO-syntaseinhibitorer